Preprint Article Version 1 This version is not peer-reviewed

Daily Low Dose of Erythropoietin and Neuroinflammation

Version 1 : Received: 5 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (16:21:35 CEST)

How to cite: Nejat, R.; Sadr, A.S.; Ebrahimi, A.; Nabati, A.; Eshaghi, E. Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints 2020, 2020060107 (doi: 10.20944/preprints202006.0107.v1). Nejat, R.; Sadr, A.S.; Ebrahimi, A.; Nabati, A.; Eshaghi, E. Daily Low Dose of Erythropoietin and Neuroinflammation. Preprints 2020, 2020060107 (doi: 10.20944/preprints202006.0107.v1).

Abstract

Neuroinflammation, defined as inflammatory reactions mediated by cytokines, chemokines, reactive oxygen species, and secondary messengers in the central nervous system (CNS) including the brain and spinal cord is the basis of many neurological disorders [1] Recently, erythropoietin (EPO) has been considered and studied as a modulator of neuroinflammation.[2-4] On this article minireview of pathophysiology of neuroinflammation and the neuroprotective effects of EPO is discussed and a case of subacute huge subdural hematoma with double mydriasis operated urgently, treated with low daily dose (vs high dose once or twice a month in the literature) of EPO and recovered fully and discharged home with good consciousness is reported. In addition, the probable outcome of erythropoietin administration in patients with neuroinflammation in COVID19 is considered.

Subject Areas

Ang II; COVID19; erythropoietin; EPO-R

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.